# Cricut, Inc.: financial statements, quarterly CRCT · Nasdaq · CIK 1828962 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/crct.md) · [Financials](/companies/crct/financials.md) · [Filings](/companies/crct/filings.md) · [Insiders](/companies/crct/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/crct/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [175](/filings/0001828962-24-000122.md) | [231 d](/filings/0001828962-26-000010.md) | [167](/filings/0001828962-25-000075.md) | [168](/filings/0001828962-25-000146.md) | [168](/filings/0001828962-25-000153.md) | [209 d](/filings/0001828962-26-000010.md) | [163](/filings/0001828962-26-000039.md) | [172](/filings/0001828962-26-000049.md) | [170](/filings/0001828962-25-000153.md) | [204 d](/filings/0001828962-26-000010.md) | [159](/filings/0001828962-26-000039.md) | [156](/filings/0001828962-26-000049.md) | | Cost of revenue | $m | [93.0](/filings/0001828962-24-000122.md) | [134 d](/filings/0001828962-26-000010.md) | [75.8](/filings/0001828962-25-000075.md) | [78.1](/filings/0001828962-25-000146.md) | [90.5](/filings/0001828962-25-000153.md) | [115 d](/filings/0001828962-26-000010.md) | [64.3](/filings/0001828962-26-000039.md) | [70.6](/filings/0001828962-26-000049.md) | [76.3](/filings/0001828962-25-000153.md) | [107 d](/filings/0001828962-26-000010.md) | [66.8](/filings/0001828962-26-000039.md) | [39.9](/filings/0001828962-26-000049.md) | | Gross profit | $m | [81.9](/filings/0001828962-24-000122.md) | [97.0 d](/filings/0001828962-26-000010.md) | [91.6](/filings/0001828962-25-000075.md) | [89.8](/filings/0001828962-25-000146.md) | [77.4](/filings/0001828962-25-000153.md) | [94.0 d](/filings/0001828962-26-000010.md) | [98.3](/filings/0001828962-26-000039.md) | [102](/filings/0001828962-26-000049.md) | [94.1](/filings/0001828962-25-000153.md) | [96.4 d](/filings/0001828962-26-000010.md) | [92.7](/filings/0001828962-26-000039.md) | [116](/filings/0001828962-26-000049.md) | | Research and development | $m | [15.9](/filings/0001828962-24-000122.md) | [15.0 d](/filings/0001828962-26-000010.md) | [14.9](/filings/0001828962-25-000075.md) | [14.3](/filings/0001828962-25-000146.md) | [15.2](/filings/0001828962-25-000153.md) | [16.0 d](/filings/0001828962-26-000010.md) | [15.7](/filings/0001828962-26-000039.md) | [16.8](/filings/0001828962-26-000049.md) | [16.9](/filings/0001828962-25-000153.md) | [17.2 d](/filings/0001828962-26-000010.md) | [16.6](/filings/0001828962-26-000039.md) | [16.9](/filings/0001828962-26-000049.md) | | Operating income | $m | [23.7](/filings/0001828962-24-000122.md) | [16.5 d](/filings/0001828962-26-000010.md) | [25.2](/filings/0001828962-25-000075.md) | [26.4](/filings/0001828962-25-000146.md) | [10.6](/filings/0001828962-25-000153.md) | [13.9 d](/filings/0001828962-26-000010.md) | [29.3](/filings/0001828962-26-000039.md) | [30.1](/filings/0001828962-26-000049.md) | [22.7](/filings/0001828962-25-000153.md) | [13.9 d](/filings/0001828962-26-000010.md) | [22.9](/filings/0001828962-26-000039.md) | [47.4](/filings/0001828962-26-000049.md) | | Interest expense | $m | [0.1](/filings/0001828962-24-000122.md) | [0.1 d](/filings/0001828962-26-000010.md) | [0.1](/filings/0001828962-24-000048.md) | [0.1](/filings/0001828962-24-000102.md) | [0.1](/filings/0001828962-25-000153.md) | [0.1 d](/filings/0001828962-26-000010.md) | [0.1](/filings/0001828962-26-000039.md) | [0.1](/filings/0001828962-26-000049.md) | [0.2](/filings/0001828962-25-000153.md) | [0.2 d](/filings/0001828962-26-000010.md) | [0.1](/filings/0001828962-26-000039.md) | [0.1](/filings/0001828962-26-000049.md) | | Income tax | $m | [8.3](/filings/0001828962-24-000122.md) | [7.2 d](/filings/0001828962-26-000010.md) | [8.6](/filings/0001828962-25-000075.md) | [10.0](/filings/0001828962-25-000146.md) | [2.7](/filings/0001828962-25-000153.md) | [4.7 d](/filings/0001828962-26-000010.md) | [8.7](/filings/0001828962-26-000039.md) | [9.4](/filings/0001828962-26-000049.md) | [5.1](/filings/0001828962-25-000153.md) | [8.0 d](/filings/0001828962-26-000010.md) | [4.8](/filings/0001828962-26-000039.md) | [11.3](/filings/0001828962-26-000049.md) | | Net income | $m | [17.2](/filings/0001828962-24-000122.md) | [11.3 d](/filings/0001828962-26-000010.md) | [19.6](/filings/0001828962-25-000153.md) | [19.8](/filings/0001828962-25-000153.md) | [11.5](/filings/0001828962-25-000153.md) | [11.9 d](/filings/0001828962-26-000010.md) | [23.9](/filings/0001828962-26-000049.md) | [24.5](/filings/0001828962-26-000049.md) | [20.5](/filings/0001828962-25-000153.md) | [7.8 d](/filings/0001828962-26-000010.md) | [20.3](/filings/0001828962-26-000049.md) | [39.1](/filings/0001828962-26-000049.md) | | Diluted EPS | $ per share | [0.08](/filings/0001828962-24-000122.md) | not reported | [0.09](/filings/0001828962-25-000075.md) | [0.09](/filings/0001828962-25-000146.md) | [0.05](/filings/0001828962-25-000153.md) | not reported | [0.11](/filings/0001828962-26-000039.md) | [0.11](/filings/0001828962-26-000049.md) | [0.10](/filings/0001828962-25-000153.md) | not reported | [0.10](/filings/0001828962-26-000039.md) | [0.19](/filings/0001828962-26-000049.md) | | Basic EPS | $ per share | [0.08](/filings/0001828962-24-000122.md) | not reported | [0.09](/filings/0001828962-25-000075.md) | [0.09](/filings/0001828962-25-000146.md) | [0.05](/filings/0001828962-25-000153.md) | not reported | [0.11](/filings/0001828962-26-000039.md) | [0.12](/filings/0001828962-26-000049.md) | [0.10](/filings/0001828962-25-000153.md) | not reported | [0.10](/filings/0001828962-26-000039.md) | [0.19](/filings/0001828962-26-000049.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [72.6](/filings/0001828962-23-000108.md) | [142](/filings/0001828962-25-000039.md) | [179](/filings/0001828962-24-000048.md) | [196](/filings/0001828962-24-000102.md) | [142](/filings/0001828962-24-000122.md) | [232](/filings/0001828962-26-000010.md) | [252](/filings/0001828962-25-000075.md) | [298](/filings/0001828962-25-000146.md) | [188](/filings/0001828962-25-000153.md) | [256](/filings/0001828962-26-000049.md) | [236](/filings/0001828962-26-000039.md) | [267](/filings/0001828962-26-000049.md) | | Current assets | $m | [586](/filings/0001828962-23-000108.md) | [620](/filings/0001828962-25-000039.md) | [596](/filings/0001828962-24-000048.md) | [611](/filings/0001828962-24-000102.md) | [541](/filings/0001828962-24-000122.md) | [580](/filings/0001828962-26-000010.md) | [561](/filings/0001828962-25-000075.md) | [599](/filings/0001828962-25-000146.md) | [441](/filings/0001828962-25-000153.md) | [500](/filings/0001828962-26-000049.md) | [462](/filings/0001828962-26-000039.md) | [500](/filings/0001828962-26-000049.md) | | Total assets | $m | [719](/filings/0001828962-23-000108.md) | [750](/filings/0001828962-25-000039.md) | [724](/filings/0001828962-24-000048.md) | [742](/filings/0001828962-24-000102.md) | [664](/filings/0001828962-24-000122.md) | [693](/filings/0001828962-26-000010.md) | [682](/filings/0001828962-25-000075.md) | [722](/filings/0001828962-25-000146.md) | [564](/filings/0001828962-25-000153.md) | [581](/filings/0001828962-26-000049.md) | [544](/filings/0001828962-26-000039.md) | [586](/filings/0001828962-26-000049.md) | | Current liabilities | $m | [174](/filings/0001828962-23-000108.md) | [196](/filings/0001828962-25-000039.md) | [153](/filings/0001828962-24-000048.md) | [276](/filings/0001828962-24-000102.md) | [171](/filings/0001828962-24-000122.md) | [203](/filings/0001828962-26-000010.md) | [171](/filings/0001828962-25-000075.md) | [393](/filings/0001828962-25-000146.md) | [187](/filings/0001828962-25-000153.md) | [221](/filings/0001828962-26-000049.md) | [170](/filings/0001828962-26-000039.md) | [201](/filings/0001828962-26-000049.md) | | Total liabilities | $m | [193](/filings/0001828962-23-000108.md) | [215](/filings/0001828962-25-000039.md) | [171](/filings/0001828962-24-000048.md) | [294](/filings/0001828962-24-000102.md) | [188](/filings/0001828962-24-000122.md) | [226](/filings/0001828962-26-000010.md) | [191](/filings/0001828962-25-000075.md) | [413](/filings/0001828962-25-000146.md) | [206](/filings/0001828962-25-000153.md) | [237](/filings/0001828962-26-000049.md) | [186](/filings/0001828962-26-000039.md) | [217](/filings/0001828962-26-000049.md) | | Shareholders' equity | $m | [526](/filings/0001828962-24-000122.md) | [535](/filings/0001828962-26-000010.md) | [553](/filings/0001828962-25-000153.md) | [449](/filings/0001828962-25-000153.md) | [476](/filings/0001828962-25-000153.md) | [467](/filings/0001828962-26-000049.md) | [490](/filings/0001828962-26-000049.md) | [309](/filings/0001828962-26-000049.md) | [358](/filings/0001828962-25-000153.md) | [344](/filings/0001828962-26-000049.md) | [357](/filings/0001828962-26-000049.md) | [368](/filings/0001828962-26-000049.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [36.4 d](/filings/0001828962-24-000122.md) | [92.1 d](/filings/0001828962-26-000010.md) | [56.7](/filings/0001828962-25-000075.md) | [35.0 d](/filings/0001828962-25-000146.md) | [70.2 d](/filings/0001828962-25-000153.md) | [103 d](/filings/0001828962-26-000010.md) | [61.2](/filings/0001828962-26-000039.md) | [36.2 d](/filings/0001828962-26-000049.md) | [20.5 d](/filings/0001828962-25-000153.md) | [82.4 d](/filings/0001828962-26-000010.md) | [26.9](/filings/0001828962-26-000039.md) | [50.4 d](/filings/0001828962-26-000049.md) | | Dividends paid | $m | [218 d](/filings/0001828962-24-000122.md) | [0.3 d](/filings/0001828962-26-000010.md) | [1.4](/filings/0001828962-25-000075.md) | [0.1 d](/filings/0001828962-25-000146.md) | [108 d](/filings/0001828962-25-000153.md) | [0.2 d](/filings/0001828962-26-000010.md) | [21.5](/filings/0001828962-26-000039.md) | [0.0 d](/filings/0001828962-26-000049.md) | [181 d](/filings/0001828962-25-000153.md) | [0.0 d](/filings/0001828962-26-000010.md) | [21.2](/filings/0001828962-26-000039.md) | [0.0 d](/filings/0001828962-26-000049.md) | | Share repurchases | $m | [0.3 d](/filings/0001828962-24-000122.md) | [15.8 d](/filings/0001828962-26-000010.md) | [10.8](/filings/0001828962-25-000075.md) | [9.3 d](/filings/0001828962-25-000146.md) | [10.4 d](/filings/0001828962-25-000153.md) | [8.0 d](/filings/0001828962-26-000010.md) | [12.0](/filings/0001828962-26-000039.md) | [4.7 d](/filings/0001828962-26-000049.md) | [2.4 d](/filings/0001828962-25-000153.md) | [5.7 d](/filings/0001828962-26-000010.md) | [12.3](/filings/0001828962-26-000039.md) | [7.5 d](/filings/0001828962-26-000049.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Dividends paid: us-gaap:PaymentsOfDividends - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [220](/filings/0001828962-23-000108.md) | [219](/filings/0001828962-24-000048.md) | [220](/filings/0001828962-24-000102.md) | [220](/filings/0001828962-24-000122.md) | [217](/filings/0001828962-25-000075.md) | [218](/filings/0001828962-25-000146.md) | [216](/filings/0001828962-25-000153.md) | [214](/filings/0001828962-26-000039.md) | [215](/filings/0001828962-26-000049.md) | [215](/filings/0001828962-25-000153.md) | [213](/filings/0001828962-26-000039.md) | [211](/filings/0001828962-26-000049.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.